Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
📈 Agilent Technologies announced FDA approval for PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic to identify eligible patients with esophageal or gastroesophageal junction carcinoma for KEYTRUDA treatment.
🏆 This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx currently available for use with Merck’s anti-PD-1 therapy KEYTRUDA.
💬 Nina Green, Agilent’s vice-president of Clinical Diagnostics, stated the approval reinforces the company’s commitment to advancing precision medicine and delivering trusted companion diagnostics.
🏛️ On March 9, 2026, Agentered agreed to acquire privately held Biocare Medical in an all-cash deal valued at $950 million to strengthen its position in cancer diagnostics.
💰 Biocare Medical has consistently generated double-digit revenue growth since 2021 and generated over $90 million in revenue in 2025, offering specialized antibodies, reagents, and instruments for cancer research.
🚀 Agilent expects the Biocare acquisition to be immediately accretive to its revenue mix and margins, with full earnings per share accretiveness anticipated roughly 12 months after closing.
🎯 The transaction is expected to close by late 2026, specifically by the end of Agilent’s fiscal fourth quarter ending October 31, making it the company’s largest acquisition since its 2019 purchase of BioTek Instruments.
🤝 Agilent will integrate Biocare into its Life Sciences and Diagnostics Markets Group to combine capabilities with its existing pathology division and serve a broader set of laboratories.
🔬 Padraig McDonnell, Agilent CEO, stated the acquisition is intended to accelerate innovation while supporting long-term value creation for shareholders.
🚀 On March 11, 2026, Agilent announced the launch of Agilent Advanced Therapeutics, a unified CDMO integrating Canadian BIOVECTRA with Colorado’s Nucleic Acid Solutions to offer end-to-end services for oligonucleotides and APIs.
💬 Analysts upgraded Agilent to Buy from Hold by Nephron Research following its recent milestones in diagnostics and acquisition strategy.
📈 Agilent is recognized as one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.
⚠️ The article includes unrelated commentary suggesting certain AI stocks may offer greater upside potential compared to Agilent, along with tariff-related disclosures.
🏢 GuruFocus reported warning signs for Agilent related to UBS, noting that the company is currently being evaluated by financial analysts.
- Agilent Technologies received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic for esophageal or gastroesophageal junction carcinoma, marking its eighth FDA-approved indication for KEYTRUDA co-therapy.
- This expanded approval reinforces Agilent's leadership in precision medicine and demonstrates its commitment to delivering trusted companion diagnostics that enable treatment with anti-PD-1 therapies.
- Agilent upgraded to Buy from Hold by Nephron Research, reflecting positive analyst sentiment on the company's stock.
- Citi has opened an upside 90-day catalyst watch on Agilent, signaling potential short-term investment opportunity for shareholders.
- Agilent is listed among 10 Best Diagnostics and Research Stocks to Buy According to Analysts, highlighting strong market positioning in its core sector.
- On March 9, 2026, Agilent entered a definitive agreement to acquire Biocare Medical for $950 million in all-cash, combining Biocare's high-growth immunohistochemistry portfolio with Agilent's pathology division.
- Biocare Medical has consistently generated double-digit revenue growth since 2021, with over $90 million in revenue in 2025, providing immediate accretive potential to Agilent's revenue mix and margins.
- The acquisition is expected to close by late 2026 and will be immediately accretive to earnings per share roughly 12 months after closing, supporting long-term value creation for shareholders.
- Agilent announced the launch of Agilent Advanced Therapeutics on March 11, 2026, integrating its Canadian BIOVECTRA with Colorado's Nucleic Acid Solutions to offer end-to-end services for oligonucleotides and APIs.
- CEO Padraig McDonnell stated that the Advanced Therapeutics launch supports the company's long-term commitment to growth in the CDMO sector.
- The Biocare acquisition represents Agilent's largest deal since its $1.17 billion purchase of BioTek Instruments in 2019, further solidifying its competitive position in cancer diagnostics.
- The article contains significant promotional content for Agilent Technologies, including analyst upgrades and positive headlines about FDA approvals and acquisitions, but also includes a specific warning section stating 'GuruFocus has detected 2 Warning Sign with UBS', indicating potential red flags not elaborated upon in the main text.
- Despite claims that the Biocare Medical acquisition will be immediately accretive to revenue and margins, the article notes earnings per share (EPS) accretivity is only expected roughly 12 months after closing, suggesting a delay in financial benefits.
- The company's largest acquisition since BioTek Instruments ($1.17 billion in 2019) and the recent $950 million purchase of Biocare carry integration risks, especially given that Biocare will be integrated into Agilent's Life Sciences and Diagnostics Markets Group which is a major operational shift.
- Jefferies Financial Group serves as financial adviser to the sellers while Ropes & Gray acts as legal adviser for Biocare, indicating complex transaction structures that could lead to deal complications or unexpected liabilities.
- The article mentions rising helium prices could create a headwind for competitor Bruker but implies similar macroeconomic pressures like inflation and tariffs may impact broader industry costs, although specific downside risks for Agilent from these factors are not explicitly quantified in the text.
